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Prostate cancer (PC) remains a significant public health concern for men throughout the 
world.  Identification of the environmental and genetic factors that predispose to PC for 
prevention or early intervention is a significant public health concern.  PC is more prevalent in 
males of African descent living in the western hemisphere.  Also, recent studies have shown high 
rates of PC in Afro-Caribbean populations.  Men in the 40-79 year age range from the Caribbean 
island of Tobago have a 3 fold higher risk of developing prostate cancer than do Caucasians.  We 
performed two candidate gene-based association studies to explore the genetic determinants for 
high risk of PC in Tobago population. 
In the first study, we performed an extensive study to identify sequence variation in the 
DC-SIGN gene, a candidate gene for PC, in the Tobago population, and carried out a 
case/control association study of DC-SIGN polymorphisms and PC susceptibility in the high-risk 
population of Tobago.  We found a unique haplotype in the 5’ proximal promoter of DC-SIGN 
that is associated with PC in Tobago.  We further extended the association study to single gene 
polymorphisms likely to be in linkage disequilibrium with DC-SIGN.  We also found that a 
single nucleotide polymorphism, rs4804806, which is located in the intragenic region between 
the DC-SIGN and DCSIGN-R genes (4228bp upstream of DC-SIGN), is significantly associated 
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with elevated risk of PC in Tobago population.  The function of rs4804806, and whether the risk 
associated with it is due to linkage disequilibrium between it and other causal variation remains 
to be explored.  
In the second study, we examined whether genetic variation in the androgen receptor (AR) 
and PSA genes was associated with risk of prostate cancer or with serum PSA levels in the 
Tobago population. Previous studies have proposed that the rs266882 G/A polymorphism, 
located in the androgen response element upstream of the PSA gene and the (CAG)n repeat 
polymorphism in DNA binding domain  of the AR are associated with risk of PC and serum PSA 
levels, and those two genetic variants show evidence of  genetic interaction. In order to examine 
whether those two genetic variants affect PC risk or PSA level in Tobago population, an 
association study was carried out in 167 PC cases and 320 controls.  Association analysis with 
PC was conducted among all cases and controls for each locus individually, and also for both 
loci together, to test for interaction between them in determining risk of PC or PSA levels.  
Regression analysis was carried out for each locus and combined with serum PSA level in 320 
controls only.  Results from this study do not provide any association evidence with PC risk or 
PSA level for PSA rs266882 G/A genotypes or AR (CAG)n repeat length genotypes.   
The results from these two studies lend support to exploring genetic causes and 
prevention of prostate cancer. 
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1.0 CHAPTER ONE: INTRODUCTION 
 
1.1 Epidemiology of Prostate Cancer 
Prostate cancer (PC) is highly prevalent, being the most common non-cutaneous cancer, 
and the second most common cause of cancer death in men. Globally an estimated 782,600 new 
cases and 254,000 deaths caused by PC occurred in 2007. (Crawford 2009)  In the United States, 
PC accounts for about 25% of all cancers diagnosed in men in 2008.   In 2008, the 5-year 
survival rate for localized or regional PC was very close to 100%.  However when it has already 
metastasized by time of diagnosis, the 5-year survival rate has been reported to be as low as 32%. 
(Jemal, Siegel et al. 2008)  With the introduction of prostate specific antigen (PSA) testing, and 
digital rectal examination (DRE) screening, more and more prostate cancer cases are being 
diagnosed at earlier stage. The only firmly established risk factors for PC are age, ethnicity and 
family history of PC.  
PC is a disease strongly associated with aging.  The probability of developing PC 
increases from 0.005% among individuals aged <39 years to 2.2% among those aged 40-59 years 
and 13.7% for Caucasian men, aged over 60-79%. (Crawford 2003) Individuals of African 
descent have the highest rates of PC in the world.  In the United States, the incidence among 
African Americans is nearly 60% higher than among Caucasians.  Moreover, the mortality rate 
for African Americans is about twice as high as for whites, 3.3 times higher than for Hispanics 
and 5 times higher than for Asians. (Crawford 2003) 
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In a recent study from the Caribbean nation of Trinidad and Tobago, the prevalence of 
screening-detected prostate cancer was three-fold higher among Tobago men of African descent 
compared to US Caucasian men. (Bunker, Patrick et al. 2002; Bunker, Patrick et al. 2002)  This 
variation between ethnic groups may be related to differences in genetic background, 
environment factors (e.g. diet, environmental exposures) and physiologic status (e.g. hormone 
levels). 
Prostate cancer is highly heritable.  The risk of developing PC doubles for men who have 
a father or brother affected by PC, and epidemiologic studies indicate that men with a positive 
family history are diagnosed on average 6-7 years earlier than those without an affected first-
degree relative.  These studies estimate that about 10% of all PC cases and up to 40% of those 
occurring at <55 years of age may have a hereditary basis. (Steinberg, Carter et al. 1990; Bratt 
2002)  These recurrence rates are estimated primarily based on Caucasian men, while the role of 
heredity in populations of African descent is not well characterized. 
Recently, some additional factors have been reported to be associated with risk of PC 
incidence.  For example, a higher intake of total fat is associated with higher risk of PC, and total 
intake of soybean products and tomato products are reported to be protective factors associated 
with lower risk of PC. (Giovannucci, Rimm et al. 1993; Whittemore, Kolonel et al. 1995) 
However, these results still remain to be replicated. 
More and more evidence suggests that chronic inflammation is a risk factor in PC.  
Firstly, chronic inflammation can cause clinical prostatitis and prostatic proliferative 
inflammatory atrophy (PIA), which has been suggested to be associated with PC and a potential 
PC precursor lesion. Secondly, studies have shown that several sexually transmitted infections 
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(STIs) are associated with PC (e.g. human papilloma virus strains HPV-16 and HPV-18).(Tu, 
Jacobs et al. 1994; Serth, Panitz et al. 1999)  Thirdly, several innate immune response related 
genes have been found to be associated with PC, such as the endo-ribonuclease gene (RNASEL) 
(Casey, Neville et al. 2002; Wang, McDonnell et al. 2002), macrophage scavenger receptor 
(MSR1) (Xu, Zheng et al. 2002; Xu, Zheng et al. 2003; Lindmark, Jonsson et al. 2004), and 
glutathione S-transferase (GSTP1) (Nelson, Kidd et al. 2001; Jeronimo, Varzim et al. 2002).   
These immune related genes play important roles in regulating pathogen infection and the 
inflammatory response.  
Recently, Hoffman et al (2004) and McDonald et al (2009) have suggested that human 
herpesvirus 8 (HHV8) may play a role in PC because of the elevated prevalence of HHV8 
seropositivity among PC cases in Tobago and among women in Tobago. (Hoffman, Bunker et al. 
2004; McDonald, Ragin et al. 2009) 
HHV-8, also known as Kaposi’s sarcoma associated herpesvirus, is the most recently 
discovered human herpesvirus. (Chang, Cesarman et al. 1994; Rivas, Thlick et al. 2001)  It is a 
member of the lymphotrophic (gamma) herpesviruses. (Rivas, Thlick et al. 2001)  HHV8 is 
known to cause Kaposi’s sarcoma, primary effusion lymphoma, and is reported to be associated 
with several other cancers. (Moore and Chang 2001; Rivas, Thlick et al. 2001; Bollen, Polstra et 
al. 2003)  DC-SIGN serves as a receptor for HHV8. (Rappocciolo, Jenkins et al. 2006)  Based on 
these findings, we hypothesized that DC-SIGN may play a role in regulating infections and 
prostatic inflammation and therefore contribute to the elevated risk of PC in Tobago. 
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1.2 Genetics of Prostate Cancer 
Prostate cancer is one of the most heritable late onset cancers.  Studies have suggested 
that around 10% of all PC cases, and up to 40% of those occurring before 55 years of age, have a 
hereditary basis. (Carter, Beaty et al. 1992; Bratt, Damber et al. 2002)  However, these studies 
are carried out primarily in Caucasian populations, and the heritability of PC among other ethnic 
groups is not well characterized.  There have been numerous genome wide and targeted linkage 
studies of PC, and implicating a large number of chromosome regions, including 1q, 2p, 6p, 8q, 
16p, 17p, 19q, 20 and the X chromosome, but these have largely failed to produce reproducible 
results.  Positional cloning has successfully identified RNASEL (HPC1, 1q24-25), MSR1 (8p32) 
and ELAC2 (HPC2, 17p2) as genes located within linked intervals and having mutations in 
prostate cancer families or patients. (Tavtigian, Simard et al. 2001; Carpten, Nupponen et al. 
2002; Xu, Zheng et al. 2002)  In the pre-genome wide association study (GWAS) era, numerous 
single gene associations were reported between PC and a wide spectrum of genes, and these 
studies were either replicated or not in subsequent studies, making any conclusion about the 
genetic basis of PC questionable.  (Vastag 2002; Freedman, Haiman et al. 2006; Gudmundsson, 
Sulem et al. 2007; Gudmundsson, Sulem et al. 2007; Yeager, Orr et al. 2007; Witte 2009) 
With the advent of GWAS studies, there have been several studies of PC reported in 
various populations, and significant association has been reported for SNP on almost every 
chromosome.  It has been concluded from these studies that PC is a complex disease with 
multiple individual genes, each with small effects contributing to risk.  Few of these studies, both 
linkage and association, have included a sufficient number of individuals of African descent to 
identify specific genes or generalize the results of studies in Caucasian populations to 
populations of African ancestry.  Interestingly none of the regions previously reported from 
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linkage studies or biological candidate studies are consistently found by GWAS. (Amundadottir, 
Sulem et al. 2006; Gudmundsson, Sulem et al. 2007; Yeager, Orr et al. 2007; Eeles, Kote-Jarai et 
al. 2008; Thomas, Jacobs et al. 2008) Whether this indicates that these play a minor role in 
determining susceptibility in the general population, or represent false positive findings is not 
known.    
PC is a testosterone dependent tumor, at least at the early stage, leading investigations to 
examine genes involved in hormone metabolism.  Among the most intensively studied biological 
candidate genes for PC is the transactivation domain encoded by exon 1 of the androgen receptor 
(AR) gene, which has 2 different tri-nucleotide repeat variants (CAG and GGC).  Some studies 
have suggested that a shorter (CAG)n repeat length is associated with increased PC risk, while 
other studies have failed to confirm such association. (Xue, Irvine et al. 2000; Chang, Zheng et al. 
2002; Gsur, Preyer et al. 2002; Medeiros, Morais et al. 2002; Salinas, Austin et al. 2005)   The 
consensus is that the variation is associated with a small but measureable increase in risk of PC.  
Another candidate gene is SRD5A2, which encodes the 5α-reductase type 2 that catalyzes the 
conversion of testosterone to the more active dihydrotestosterone.  The Ala49Thr mutation in 
SRD5A2 increases its catalytic activity and could therefore increase PC risk. (Makridakis, Ross 
et al. 1999) The results remain equivocal. (Li, Coates et al. ; Ntais, Polycarpou et al. 2003) 
Genes involved in immune response are also promising targets for PC candidate-gene 
studies, because those genes play important role in infections and chronic inflammation, both of 
which are important PC risk factors.  Recent studies have shown that sequence variation in genes 
related to the early immune response, such as the endo-ribonuclease gene RNASEL, macrophage 
scavenger receptor (MSR), glutathione S-transferase (GSTP1) increase the risk of PC. (Palapattu, 
Sutcliffe et al. 2005)  
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1.3 Tobago Population 
Tobago is the smaller of the two main islands that make up the Republic of Trinidad and 
Tobago. It is located in the southern Caribbean Sea, northeast of the island of Trinidad and south 
of Grenada.  Tobago is a land area of 300 km2, and is approximately 42km long and 10km wide. 
(Fig. 1)  The population is around 60,000.  While Trinidad is multiethnic, the Tobago population 
is overwhelmingly Afro-Tobagonian.  The population of Tobago was reported to be 92 percent 
black, 4.5 percent mixed, 2 percent East Indian, 0.4 percent white, and 1 percent other in the 
1990 census.   This distribution is very different from the 38 percent black, 20 percent mixed, 42 
percent East Indian, and 0.3 percent white/other reported in the total Trinidad & Tobago 
population. (Central Statistical Office of Tobago 1993; Boyd-Patrick HA 1997 )  The older 
population of the island appears to be a stable population of descendents of West African 
forbears who arrived around 200 years ago.  They are thought to share considerable West 
African Ancestry with African Americans.  The Tobago population of non-African descent has 
been very small throughout this time period, and genetic admixture appears to be relatively low. 
(Miljkovic-Gacic, Ferrell et al. 2005) This low admixture rate makes it very suitable population 
for genetic research. 
Men in the 40-79 year age range from the Caribbean island of Tobago have a 3-4 times 
higher risk of developing prostate cancer than do Caucasians.(Bunker, Patrick et al. 2002)  And 
elevated human herpesvirus 8 (HHV-8) seroprevalence has been reported in among Tobago 
prostate cancer cases. (Hoffman, Bunker et al. 2004)  Therefore, we hypothesize that genetic 
variation in the HHV-8 immune receptor DC-SIGN is associated with elevated HHV-8 
seroprevalence and risk of prostate cancer in men of Tobago in our first candidate-gene based PC 
study. 
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Figure 1:  Geographic information on Tobago 
Geographic view of Tobago generated by Google Earth software.  (earth.google.com) 
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2.0 CHAPTER TWO: PROSTATE CANCER ASSOCIATION STUDY OF 
DC-SIGN GENE IN THE TOBAGO POPULATION 
 
2.1     Background and Introduction to DC-SIGN 
Dendritic cell-specific ICAM-3-grabbing non-integrin (DC-SIGN; CD209) is a type II C-
type lectin that functions as an adhesion receptor and mediates viral binding and internalization.  
It is expressed in dendritic cells (DCs), macrophages, and B cells, and is exploited by many 
pathogens, such as HIV-1, Ebola virus, and HHV-8, to gain entry to the cell. (Geijtenbeek, Kwon 
et al. 2000; Alvarez, Lasala et al. 2002; Rappocciolo, Jenkins et al. 2006)  Interestingly, 
epidemiological data has suggested that PC cases in Tobago also have an elevated rate of viral 
infection including HHV-8. (Hoffman, Bunker et al. 2004)  Therefore, genetic variants of DC-
SIGN may regulate viral infection, and further contribute to the high risk of PC in Tobago 
population. 
The DC-SIGN gene (CD209) is located on human chromosome 19p13, in a multigene 
cluster that also contains genes encoding the lectins DC-SIGNR (CD209L), FceRII(CD23) and 
LSECtin (CLEC4G).  DC-SIGN and DC-SIGNR are 73% identical at the amino acid level and 
both genes are heavily alternately spliced, giving rise to many isoforms with a variety of 
localizations. (Soilleux, Barten et al. 2000) 
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DC-SIGN is a small type II trans-membrane C-type lectin consisting of 404 amino acids 
with three distinct domains. (Geijtenbeek, Torensma et al. 2000) The N-terminal cytoplasm 
domain of 40 amino acid residues contains two putative internalization motifs (one di-leucine 
motif and a tri-acidic cluster motif), and is critical for antigen internalization. The 
transmembrane domain consists of 7 complete and one incomplete repeats of nearly identical 
sequences, each repeat encoding 23 amino acids, and is important for DC-SIGN oligomerization, 
carbohydrate recognition and normal DC function. (Geijtenbeek, Torensma et al. 2000; Feinberg, 
Guo et al. 2005; Snyder, Ford et al. 2005)  It has recently been reported that the neck region also 
acts as a pH-sensor in physiological conditions to regulate DC function. (Tabarani, Thepaut et al. 
2009)  The extracellular C-terminal domain is required for glycoprotein binding.  DC-SIGN 
plays a critical role on almost every aspect of normal DC function, including antigen recognition 
and binding, antigen endocytosis and presentation, DC migration, and DC-T cell interaction. 
(Geijtenbeek, Krooshoop et al. 2000; Engering, Geijtenbeek et al. 2002; Frison, Taylor et al. 
2003; Guo, Feinberg et al. 2004; Feinberg, Guo et al. 2005) 
 
2.2 Specific Aims 
Aim 1: To dissect the genetic architecture of the DC-SIGN gene in the Tobago 
population. 
Aim 2: To test whether DC-SIGN genetic polymorphism is associated with elevated 
HHV-8 seroprevalence in the Tobago population. 
Aim 3: To test whether DC-SIGN genetic polymorphism is associated with elevated risk 
of PC in the Tobago population. 
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2.3 Experiment Design 
We chose a sample of 41 controls and 39 PC cases, and carried out a comprehensive 
genotypic screening, covering the entire DC-SIGN gene region (5’ UTR, 7 exons, 6 introns and 
3’UTR) using DHPLC and ABI BigDye sequencing techniques.  Using the data we collected, we 
examined linkage disequilibrium (LD) and haplotype structure of DC-SIGN the Tobago 
population to accomplish Aim 1. 
Based on the polymorphism and LD information from the initial screening, we further 
chose the most informative SNPs and potentially important regions, and extensively genotyped 
these SNPs and regions in a larger group of case and control samples.  We achieved Aim 2 and 3 
by case-control analysis based on the genotypic data we obtained. 
 
2.4 Materials and Methods 
2.4.1 Subjects 
Subjects were drawn from the Tobago Prostate Survey, an ongoing population based 
screening study of men 40-79 years old on the Caribbean Island of Tobago. (Bunker et al. 2002)  
Recruitment was by word of mouth, posters, fliers, public health announcements and healthcare 
workers.  A total of 2582 men aged 40 to 79 years old (50% of all Tobago men in this age group) 
were screened using both serum prostate-specific antigen (PSA) and digital rectal examination 
(DRE). Prostate cancer cases are further ascertained in men with elevated PSA level (4ng/mL or 
greater) or abnormal DRE by ultrasound-guided sextant biopsy. 
Prior to screening, all participants gave written informed consent following procedures 
approved by the University of Pittsburgh and the Tobago Division of Health and Social Services 
institutional review boards.  Fifteen milliliters of fasting peripheral blood was drawn prior to a 
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physician administered digital rectal exam (DRE), and prostate specific antigen (PSA) measured 
by the University of Pittsburgh Medical Center Pathology Laboratories.  All subjects with an 
elevated PSA level (>
 HHV-8 seropositivity was determined by either indirect immunofluorescence assay (IFA) 
or a combination of enzyme-linked immunosorbent assay and IFA by Dr. Frank Jenkins. Details 
are given in Jenkins et al (
4 mg/ml) or abnormal DRE findings (except simple enlargement) were 
referred to the Tobago Regional Hospital for six core, ultrasound-guided biopsy by surgeons 
trained by urologists from the University of Pittsburgh.  Details are given in Bunker et al (2002; 
2004). 
J Infect Dis. 2004, 189:15-20). 
Initial screening of 80 individuals (41 controls and 39 cases) was followed by sequencing 
2kb of the 5’ region of DC-SIGN in additional 153 cases and 172 controls. 
 
2.4.2 ABI Sequence Analysis of DC-SIGN 
Genomic DNA was isolated from peripheral blood leucocytes by standard procedures 
(Puregene, Gentra Systems).  To obtain sufficient DNA, samples were whole genome amplified 
using the method of Dean et al. using the Genomiphi (Amersham Biosciences) whole genome 
amplification protocol. (Dean, Hosono et al. 2002)  Briefly, 1 μl of DNA, at a concentration of 
approximately 40 nanograms/μl, was added to 9 μl of sample buffer containing random 
hexamers and heated to 95°C to denature the DNA.  The sample was cooled and mixed with 9 μl 
of reaction buffer containing salts and deoxynucleotides and 1 μl of Phi 29 DNA polymerase 
enzyme mix.  The mixture was incubated overnight at 30°C. After amplification, the Phi29 DNA 
polymerase was heat-inactivated by a 10 minute incubation at 65°C.  All DNA samples used in 
this project were provided by Dr. Bunker.  
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2 kb of the 5′ -promoter region, the exons, and 1 kb of the 3′ -UTR were screened. All 
exons, exon-intron boundaries, proximal 5’ and 3’ untranslated regions were thoroughly covered.  
Unique sequence primers for each region were designed using MACVECTOR software.  
(www.macvector.com) 
Amplifications were carried out by using Taq DNA polymerase kit (Invitrogen 
Corporation, CA). 20 ng of DNA was added to a reaction mixture, including 4pmoles of each 
primer pair (Table 1), 10nmoles of each dNTP, 2μl of 10xbuffer, 1 μl of MgCl2 (Table 1),  and 
1U of Taq DNA polymerase.  The final total reaction volume was adjusted to 20 μl by adding 
deionized water.  Samples were denatured at 95°C for 2 min. followed by cycles [table1] of 
denaturation at 95°C for 30 sec, annealing at temperatures indicated in Table 1 for 30 sec. and 
extension at 72°C for 1 min.  All amplimers (5μl) were resolved by electrophoresis in 2% 
agarose gel, stained with ethidium bromide and visualized under UV illumination to confirm the 
size and purity of the products. 
The ExoSAP process was used to clean up the PCR products before sequencing. Briefly, 
5μ PCR product was incubated with 5μ master mix of ExoSAP (0.5μl shrimp alkaline 
phosphatase, 0.05μl of exonuclease I, 0.5μl buffer and 4ul deionized water) at 37°C for 30 min. 
followed by denaturation at 88°C for 15 min.   Amplimers were sequenced from both directions 
using the ABI Bigdye Terminator Ready Reaction kits (Applied Biosystems, Forest City, CA) as 
described in the manufacturer’s protocol. Briefly, 2.5μl PCR product, 2.3μl primer (0.8μM), 
0.575ul dRhodamine dye and 1.725μl of sequencing buffer together were mixed together, and 
the reaction mixture was incubated at 96°C for 10 seconds, 50°C for 5 seconds and 60°C for 4 
minutes, repeated for 24 cycles.  Products were cleaned by ethanol precipitation procedures.  
Briefly, 5μl of EDTA and 60μl of 100% ethanol was added to each well of the optical 96-well 
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plate.  The mixture was incubated at room temperature for 15min and centrifuged at 2500xg for 
30min at 4°C and supernatant was removed.  The DNA then was washed with 70% ethanol and 
centrifuged at 1650xg for 15min at 4°C. The fragments were separated on an ABI-3630XL 
capillary sequencer.  All sequence analysis was carried out in the University of Pittsburgh 
Genomics and Proteomics Core Laboratory (www.genetics.pitt.edu).  Sequences were aligned 
and curated using the program SEQUENCHER (Gene Codes Inc).   
 
2.4.3 DHPLC 
The exon 4 repeat variant was analyzed by denaturing high performance liquid 
chromatography (DHPLC) using a Varian Helix System. (Varian Associates Inc.) 
Denaturing High Performance Liquid Chromatography (DHPLC) (Underhill, Jin et al. 
1997) is a relatively recent technique for the detection of single base substitutions and small 
insertions/deletions in PCR products.  The DHPLC system (Varian, Inc., Walnut Creek CA; 
Helix System) uses Ion-Pair Reverse Phase (IP-RP) chromatography to separate out DNA 
fragments.  In HPLC, a stationary phase contained in the column is used to retain samples, and a 
mobile phase is used to release the sample off the column.  For DNA IP-RP applications, the 
stationary phase is comprised of hydrophobic media.  The mobile phase is a mixture of an 
aqueous buffer with an organic co-solvent (acetonitrile) and a counter ion of opposite charge 
from the sample DNA molecule (triethylammonium acetate – TEAA).  The TEAA counter ion in 
the buffer is positively charged and forms pairs with the negatively charged phosphate groups of 
DNA, thus coating the DNA molecule in a hydrophobic layer.  The number of TEAA molecules 
attached to the DNA is proportional to the length of the DNA fragment, therefore determining 
the degree to which the DNA is retained by the stationary phase.  The coated DNA molecule is 
  14 
Table 1: Amplification primer sequences and sequencing reaction components and conditions for 
DC-SIGN 
Amplified 
region 
Forward 
Reverse Primers 
Annealing  
Temp 
(°C) 
Mg2+ 
(mM) Cycles 
Prom 1 
PR1F TGGTTCCTTGGAGTCACTCATGTC 
59 2 35 
PR1R CATGCACTGTGGAGGCAGACTG 
Prom2 
PR2F CCTGCTGGTTTCTTCACATCATC 
60 2.5 35 
PR2R TTCCTGCTGACTTTGGGAGTTG 
Exon 1 and 
2 
1&2F GCAGGAGTTCTGGACACTGG 
60 2 35 
1&2R AGGAACCCAGGCCCAAGT 
Exon 3 
3F GGTGCTGAGGGATTTAGACC 
58 2 35 
3R ACACTGACACCTGGAGAAGG 
Exon 4 
4F AGGAGGAGGAGGACAGGAAG 
59 2 35 
4R TCAGAACAGAAGGCAGGAGACTG 
Exon 5 
5F TGTGATCATTGCCCTCAGTG 
60 2 35 
5R TCCCTCATTCATATCCTTCTCC 
Exon 6 
6F GCTTCTGGCTCCAACACATT 
60 2.5 35 
6R GCTGTCTGGAAGTGGGTATGA 
Exon 7 
7F GAGAAGAGAGGCAGGAACTCAAGG 
60 2.5 35 
7R GACAAGAAGGACAGAATGGGACC 
3' UTR 
3' F TGGATCTGCAAAAAGTCCGC 
59 2.5 35 
3' R AGGAGAGGCACAATTCACCTAGC 
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absorbed to the column matrix until it is exposed to a specific concentration of acetonitrile in the 
mobile phase. The application of an increasing acetonitrile gradient releases the sample in order 
of increasing length, with smaller fragments eluting first and larger fragments eluting later.  The 
DNA that is eluted from the column is detected by ultra-violet light absorption at a wavelength 
of 260nm using a uv/vis detector supplied with the DHPLC apparatus. 
 
2.4.4 TDI-FP Genotyping 
TDI-FP stands for Template directed Dye Terminator Incorporation assay with detection 
by Fluorescence Polarization.  It is a single base primer extension assay coupled with 
homogeneous FP detection.  The TDI-FP protocol was first reported in 1999. (Chen, Levine et al. 
1999)  There are four major steps to this assay: (i) template amplification by PCR; (ii) PCR 
product clean-up by Exo-SAP-It reagent; (iii) single-base primer extension using a primer that 
anneals one base 5’ of the polymorphic site and incorporates fluorophore labeled terminators; (iv) 
FP reading and data analysis. (Fig 2) 
PCR amplifications were carried out in a total reaction volume of 20 μl, containing 20ng 
of DNA, 4 pmoles of each primer, 4 nmoles of each dNTP, 2.0ul of 10xbuffer, 0.8μl of 25mM 
Mg2+ (Table 2) and 0.9U Taq DNA polymerase.  The amplification and amplicon check 
procedures were the same as described before.  Excess PCR primers and unincorporated dNTPs 
were degraded by ExoSAP process (USB Corporation, Cleveland, Ohio, USA). 10μl PCR 
product was incubated with a 10μl master mix of ExoSAP (1μl shrimp alkaline phosphatase, 
0.1μl of exonuclease 23I, 1μl buffer and 8μl deionized water) at 37°C for 90 min., followed by 
denaturation at 95°C for 15 min. 
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The TDI-FP assay previously described (Chen, Levine et al. 1999; Kwok 2002) was then 
performed for high throughput genotyping.  The cleaned PCR product (total volume 20μl) was 
combined with 0.05 μl Thermosequenase DNA polymerase (USB corporation, OH), 1.0μl 10X 
reaction buffer, 0.05μl of the 1:16 two-dye mix (eg. for SNP C/T, 16μl 0.1mM ddATP, 16μl 
0.1mM ddGTP, 15μl 0.1mM ddCTP, 16μl 0.1mM ddTTP, 1μl R110-UTP, 1μl TAMRA-CTP) 
(Perkin Elmer Life Sciences, Inc, Boston, MA), 1.0μl 10μmol/L SNP specific, and 8μl water. 
Template-directed incorporation (TDI) was performed in 96-well, black-skirted plates (MJ 
Research, Waltham, MA) using an Eppendorf cycler under the following conditions: 
denaturation at 95°C for 1 min, followed by 35 cycles of denaturation at 94°C for 10s and 
simultaneous annealing and extension at the appropriate temperature (table 2) for 30s with a final 
hold step of 4°C.  FP was measured by L.J.L Biosystem’s Analyst HT Assay Detection System 
and analyzed by Allele Caller software package (L.J.L Biosystems, Sunnyvale, CA). The 
amplification and TDI-FP primers and conditions were summarized in Table 2.     
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Figure 2:  TDI-FP assay Principle and Procedures 
Dideoxynucleotide dye-terminators were used in our assay.  
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Table 2: Amplification primer sequences and conditions and FP detection primer sequences for 
each FP locus 
SNP 
ID 
(RS#) 
Position 
(relative 
to DC-
SIGN 
start 
codon) 
Primers Annealing Temp(°C) 
Mg2+ 
(mM) 
rs7352
40 
-939 
PCR-F TCTCCACCTGCTCCTTCCTGATAA 
60 2 
PCR-R GTGTCCACCAGCAGGTGAATGATA 
FP-F CTGTGGTCCCCAGGAGTCCTG 
55  
FP-R CCCCAAGACCCAAGAATCTGG 
rs4804
806 
-4228 
PCR- AAGACAGCCATCAGCACTACGG 
60 2.5 
PCR-R GCACTGACTGGTCTCCAACTTAGG 
FP-F GAACATTCGGCTGTAGTGCCATGT 
55 
 
FP-R TGGTCAGAGTGGCTGGTCCCACAT 
rs1010
047 
18895 
PCR-F AAGGGCCTGTCTCAGGATGCCCATA 
59 2 
PCR-R TGGGACCGCTGCATTCTGGTCTA 
FP-F GGACACCTGAAGCATTTGGAAGGG 
55 
 
FP-R TCCCTCTCCCCAAAGACAAAGGTG 
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2.5 Data Analysis 
2.5.1 Single SNP association test 
For single SNP, we tested its genotype frequencies for fit to Hardy-Weinberg equilibrium 
expectation in cases and controls, using the χ2 test with one degree of freedom. 
 
2.5.2 Linkage Disequilibrium 
The linkage disequilibrium (LD) relationships between the SNPs were investigated using 
the analysis program Ldmax, and the results displayed using the GOLD program.  Ldmax uses 
the expectation-maximization algorithm of Slatkin and Excoffier (1995) to estimate linkage 
statistics.  Haplotype frequencies for all marker pairs are calculated, and a table summarizing LD 
statistics in the region can be output, and displayed graphically by software GOLD. (Fig. 3) 
(http://www.sph.umich.edu/csg/abecasis/gold/index.html) 
 
2.5.3 Haplotype construction and association analysis 
Haplotype construction and case-control significance tests were done using a Bayesian 
MCMC algorithm, implemented in the PHASE software package. (Stephens, Smith et al. 2001) 
(http://stephenslab.uchicago.edu/software.html) 
 
2.6 Results 
2.6.1 DC-SIGN sequence variations  
From the pilot screening, a total of 40 single nucleotide polymorphisms (SNPs) were 
identified, as shown in Table 3.  There is only one SNP (within exon 7) in the coding sequence 
of DC-SIGN, and this does not cause an amino acid change.  Most variations were found in the 
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5’ UTR, and SNPs in 5’UTR were in LD with each other. (Fig 3) Variations in the regulatory 
elements of DC-SIGN may affect the transcriptional activity and thus contribute to the elevated 
risk of viral infection or PC.  Therefore a detailed screening of 2kb of the promoter region of 
DC-SIGN was carried out in 153 PC cases and 172 controls from Tobago. 
 
Table 3: Locations and allele frequencies for SNPs within a 6Kb region across DC-SIGN in 80 
Tobago samples 
Relative 
position1 Location 
Minor Allele 
Frequency (MAF) Allele 
Reference 
Sequence # 
-1880 5'UTR 26.90% G/A rs8111321 
-1827 5'UTR 0.50% C/T This report2 
-1706 5'UTR 9.90% T/C rs11465355 
-1605 5'UTR 1.10% T/C rs11465356 
-1530 5'UTR 2.70% A/C rs11465352 
-1509 5'UTR 2.20% G/A rs7392155 
-1466 5'UTR 4.40% C/T rs4804804 
-1275 5'UTR 1.10% G/A rs1146772 
-1180 5'UTR 27.40% A/T rs7359874 
-1089 5'UTR 0.50% C/A rs11465360 
-1026 5'UTR 1.60% C/T This report2 
-939 5'UTR 28.30% C/T rs735240 
-336 5'UTR 49.40% T/C rs4804803 
-201 5'UTR 6.60% C/A rs11465366 
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Table 3 continued. 
Relative 
position1 Location 
Minor Allele 
Frequency (MAF) Allele 
Reference 
Sequence # 
-139 5'UTR 18.20% C/T rs2287886 
216 Intron 1 44.10% C/G rs7252229 
262 Intron 1 7.60% G/T rs11469369 
451 Intron 1 2.90% G/T rs11465371 
467 Intron 1 7.10% G/A rs11465322 
3070 Intron 5 19.90% G/A rs8105572 
3114 Intron 5 14.00% G/C rs8105483 
3173 Intron 5 0.50% C/T This report2 
4234 Intron 6 38.80% C/G rs11465391 
4238 Intron 6 6.30% G/T rs11465392 
4442 Exon7 9.30% C/T rs11465393 
4655 3'UTR 1.10% C/G rs11465395 
4787 3'UTR 22.10% C/T rs4084802 
4847 3'UTR 13.60% C/T rs10403018 
4915 3'UTR 34.30% A/T rs480410 
4920 3'UTR 0.50% A/T This report3 
4939 3'UTR 1.60% T/C rs11465396 
5147 3'UTR 18.90% C/T rs11465397 
5194 3'UTR 31.90% G/A rs6603119 
5226 3'UTR 33.00% C/T rs7248772 
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Table 3 continued. 
Relative 
position1 Location 
Minor Allele 
Frequency (MAF) Allele 
Reference 
Sequence # 
5238 3'UTR 3.30% G/A rs11465400 
5282 3'UTR 12.20% C/T rs11465401 
5370 3"UTR 42.00% C/T rs7248637 
5470 3'UTR 7.10% C/T rs11465402 
 
1 Numbered with reference to GENBANK entry NM021159.2 
2 These SNPs were not found from dbSNP, and no known SNPs nearby 
3 rs4804801 is registered 5bp from this locus, could represent the same SNP due to mis-labeling 
of its position. 
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Figure 3:  DC-SIGN SNP Pairwise D’LD plots in Tobago. Linkage disequilibrium plot for all 
SNPs from Table 3 is generated by GOLD software.  LD on exon 4 repeat region is not included 
because no genotype data is available.  High LD regions (red blocks) are mostly clustered in 5’ 
and 3’ UTR of the gene. 
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2.6.2 DC-SIGN Promoter region variations 
A total of 26 promoter region SNPs were identified in our study, of which 17 have a 
minor allele frequency (MAF) of greater than 1%. (Table 4)  The SNPs are in high LD with each 
other. (Fig 4) A total of 5 SNPs have a minor allele frequency over 10%.  We ran both allele and 
genotype association tests on these 5 common SNPs, and none gave a statistically significant 
result at the cut-off p-value of 0.05, although two gave a marginally significant p value. (Table 5 
and Table 6)  This suggested that combination of SNPs among multiple loci, rather than a single 
SNP, might be important.  Therefore we used the 5 Tag SNPs from Table 5 to generate promoter 
haplotypes of DC-SIGN.  An association analysis was performed for haplotype distributions 
among cases and controls using PHASE software. 
 
Table 4: Locations and allele frequencies for SNPs within the 2kb promoter of DC-SIGN in 325 
Tobago samples 
Position Minor  Allele freq Allele Reference Sequence number 
-1880 24.50% G/A rs8111321 
-1706 6.10% T/C rs11465355 
-1605 1.00% T/C rs11465356 
-1530 1.70% A/C rs11465357 
-1509 1.40% G/A rs73921551 
-1466 1.80% C/T rs4804804 
-1463 1.50% G/A N/A 
-1275 0.80% G/A rs11465359 
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Table 4 continued. 
Position Minor  Allele freq Allele Reference Sequence number 
-1180 29.10% A/T rs7359874 
-1089 0.10% C/A rs11465360 
-1026 2.10% C/T N/A 
-939 28.30% C/T rs735240 
-899 0.40% C/T N/A 
-871 1.70% T/C rs735239 
-866 0.10% T/C N/A 
-819 1.70% T/C rs8112852 
-802 0.80% A/T N/A 
-745 6.10% C/A rs11465362 
-670 0.30% G/A rs11465363 
-601 5.80% C/T rs11465364 
-462 0.30% T/A N/A 
-460 0.60% C/T rs11465365 
-336 44.10% T/C rs4804803 
-201 7.60% C/A rs11465366 
-171 0.30% G/A N/A 
-139 24.50% C/T rs2287886 
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Table 5: Tag SNPs used to construct DC-SIGN promoter haplotypes 
Position Rs# Alleles 
Frequenc
y in cases 
(2N=344) 
Frequency 
In controls 
(2N=306) 
p-value 
for each 
SNP 
frequency 
among 
cases and 
controls 
OR (95% CI) 
-1880 rs8111321 
G 265(0.770) 227(0.741) 
0.45 1.31 (0.59–2.89) 
A 79(0.230) 79(0.259) 
-1180 rs7359874 
A 250(0.727) 212(0.693) 
0.23 1.38 (0.70–2.73) 
T 94(0.273) 94(0.307) 
-939 rs735240 
C 260(0.756) 208(0.681) 
0.17 1.83 (0.87–3.87) 
T 84(0.244) 98(0.319) 
-336 rs4804803 
T 176(0.513) 173(0.565) 
0.11 0.60 (0.33–1.07 
C 168(0.487) 133(0.435) 
-139 rs2287886 
T 84(0.245) 75(0.244) 
0.83 0.98 (0.44–2.18) 
C 260(0.755) 231(0.756) 
Abbreviations: CI = confidence interval; OR = odds ratio. 
Numbers of chromosomes (2N analyzed). 
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Table 6:  Genotype association with PC for the 5 common SNP loci, which were used to 
generate haplotypes 
Position Genotype Cases N (%) Controls N (%) OR  (95% CI) 
-1880 
G/G 93 (60.8%) 97 (56.4%) 1.00  (Ref) 
G/A 49 (32.0%) 60 (34.9%) 1.17  (0.73-1.88) 
A/G 11 (7.2%) 15 (8.7%) 1.31  (0.57-2.99) 
-1180 
A/A 85 (55.6%) 88 (51.2%) 1.00  (Ref) 
A/T 53 (34.6%) 62 (36.0%) 1.13  (0.70-1.81) 
T/T 15 (9.8%) 22 (12.8%) 1.42  (0.69-2.91) 
-939 C/C 90 (58.5%) 82 (47.4%) 1.00  (Ref) 
 C/T 52 (34.0%) 71 (41.3%) 1.49  (0.94-2.39) 
 T/T 11 (7.2%) 19 (11%) 1.89  (0.85-4.22) 
-336 T/T 50 (32.7%) 62 (36.0%) 1.00  (Ref) 
 T/C 58 (37.9%) 78 (45.3%) 1.08  (0.66-1.80) 
 C/C 45 (29.4%) 32 (18.6%) 0.57  (0.31-1.03) 
-139 T/T 13 (8.5%) 15 (8.7%) 1.00  (Ref) 
 T/C 49 (32.0%) 55 (32.0%) 0.97  (0.42-2.24) 
 C/C 91 (59.5%) 102 (59.3%) 0.97 (0.44-2.15) 
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Figure 4: Linkage disequilibrium plot for the 26 SNPs within DC-SIGN promoter region 
Linkage disequilibrium plot for all SNPs from Table 4 is generated by GOLD software. Red 
block indicates high LD, thus this figure shows high LD throughout the entire promoter region. 
 
2.6.3 DC-SIGN Promoter Haplotype Association with PC 
The haplotype distributions between PC cases and controls were significantly different 
with a p-value of 0.03. (Table 7 and Figure 5)  This was mainly due to highly divergent 
frequencies of two haplotypes GATTC and GACTC that differ only by a single C/T SNP 
rs735240. (Table 7 and Figure 5)  However, none of the odds ratio tests for the 5 individual 
SNPs were statistically significant at cut-off p-value of 0.05. (Table 5)  Haplotype “GATTC” and 
“GACTC” showed significant association with PC as shown in Table 7.  However, we calculated p-value 
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for each haplotype assuming all the haplotype frequencies are observations instead of estimates, therefore 
we need to be more conservative on those association results.  These observations, combined with the 
fact that distributions of other haplotypes containing rs735240 are not distinct between cases and 
controls, suggest that complex haplotype structures rather than a single SNP may play an 
important role in PC susceptibility.  
 
2.6.4 DC-SIGN Promoter Haplotype Association with HHV-8 
While this DC-SIGN promoter haplotype is statistically significantly associated with 
elevated risk of PC in Tobago population (p=0.03), we did not find any haplotype association 
with HHV-8 serological status (p=0.28).  We also did a stratified analysis for haplotype 
distribution among PC cases based on their HHV-8 serological status using PHASE software, 
and no significant difference was detected for haplotype distribution among PC cases with and 
without HHV-8, suggesting that no interactions occurred. (data not shown) These results suggest 
that association of DC-SIGN promoter haplotypes with prostate cancer risk is not due to their 
role in HHV-8 infection.  Other pathogens, or other genes in LD with DC-SIGN promoter 
haplotype, may be causal to such association. 
 
2.6.5 Extended genotypic association  
To test whether the association we found was due to LD with other nearby causal loci,  
two additional tag SNPs from HapMap were picked up to extend the coverage into nearby 
chromosome regions.  These were genotyped in cases and controls in order to test whether the 
haplotype association is due to LD with nearby genes or loci.  SNP rs1010047 is located near the 
LSEctin gene, while SNP rs4804806 is located in the gap between DC-SIGN and DC-SIGNR.  
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Both these SNPs were in LD with rs735240 (-939), which is the major locus that contributes 
most to the haplotype association we found with PC in Tobago. (Figure 6)  Both SNPs were 
genotyped by FP and the allelic frequencies were summarized in Table 8.  
 
Table 7:  DC-SIGN haplotype frequencies in prostate cancer cases and controls 
Haplotype Freq in controls Freq in cases p-value2 
GACCC 0.3207 0.3885 0.25 
GACTT 0.1825 0.1439 0.43 
GATTC 0.1667 0.0259 0.01 
ATTTC 0.1068 0.0563 0.14 
ATCCC1 0.0738 0.014 N/A 
GACTC 0.0523 0.1683 0.02 
ATTTT1 0.0242 0.0475 N/A 
ATCTT1 0.0223 0.0066 N/A 
GTCCC1 0.0222 0.0299 N/A 
ATTCC1 0.0062 0.0676 N/A 
GATCC1 0 0.0128 N/A 
GTTTT1 0 0.0133 N/A 
 
1Haplotype with a frequency of <5% in cases and controls were pooled, and p-valued are not 
estimated for these subgroups. 
2 Null hypothesis: haplotype frequencies are the same between cases and controls 
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Figure 5: Haplotype distribution in prostate cancer cases and controls. Frequencies for each 
haplotype were sorted and displayed in the order of frequencies in controls.  Two haplotypes 
(GATTC and GACTC), which differ most between cases and controls are highlighted in red.   
 
Both SNPs are in high LD with rs735240 (-939) in our samples, which is consistent with 
the Hapmap result.  Genotypic association with PC for each individual SNP was summarized in 
Table 9.  While we did not see any association for rs1010047, we found a statistically significant 
association with PC for rs4804806.  Odds ratio of genotype GG to GA genotype is 0.47 with 
95% CI of (0.28-0.81), and odds ratio of genotype GG to AA is 0.34 with 95% CI of (0.18-0.64).  
This suggests that rs4804806 is significantly associated with elevated risk of PC, and that the A 
allele of this locus appears to be a dominant risk allele for PC in Tobago population. 
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Figure 6: DC-SIGN and neighboring genes, and relative positions of the TAG SNPs we used for 
extended genotyping and association analysis.  
 
Table 8: Summary of allele frequencies of the two extended SNPs 
position allele MAF in all 
MAF in 
controls 
MAF in 
cases 
reference sequence 
number 
18895 A/G 38.9% (G) 
40.40% 38.80% 
rs1010047 
(G) (G) 
-4228 G/A 46.6% (A) 
40.10% 53.90% 
rs4804806 
(A) (A) 
 
 
Table 9:  Genotype association with PC for 2 extended SNPs 
Position Genotype Cases N (%) Controls N (%) OR  (95% CI) 
rs1010047 
(+18895bp) 
G/G 25 (16.3%) 38 (22.1%) 1.00  (Ref) 
G/A 63 (41.2%) 63 (36.6%) 0.66  (0.36-1.22) 
A/A 65 (42.5%) 71 (41.3%) 0.72  (0.39-1.32) 
rs4804806 
(-4228bp) 
G/G 31 (20.3%) 64 (37.2%) 1.00  (Ref) 
G/A 79 (51.6%) 78 (45.3%) 0.47  (0.28-0.81) 
A/A 43 (28.1%) 30 (17.4%) 0.34  (0.18-0.64) 
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2.6.6 Extended haplotype association with PC 
rs4804806 is over 4kB upstream of the DC-SIGN gene, but it is still close enough to be 
within the 5’ regulatory region of the gene.  We therefore reconstructed the promoter haplotype 
adding rs4804806 in additional to the 5 SNPs previously used in Table 5.  The extended 
haplotypes were summarized in Table 10, and the extended haplotype distribution among PC 
cases and controls is still significantly different (p-value=0.01).  Such association is mostly 
caused by the added rs804806 SNP because most haplotypes with the A allele at this locus are 
overrepresented in cases than controls, as seen in Figure 7. 
 
Table 10:  DC-SIGN promoter region haplotype frequencies in prostate cancer cases and 
controls adding rs4804806 
 
 
  
 
Haplotype Freq in controls Freq in cases 
GGACCC 0.212 0.198 
AGACCC 0.148 0.24 
GGACTT 0.116 0.066 
GGATTC 0.101 0.012 
AGACTT 0.093 0.098 
AGATTC 0.067 0.016 
GATTTC 0.064 0.026 
GATCCC 0.044 0 
AATTTC 0.043 0.04 
GGACTC 0.031 0.087 
AATCCC 0.03 0.008 
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Figure 7:   Haplotype distribution in prostate cancer cases and controls adding rs4804806 
Frequencies for each haplotype were sorted and displayed in the order of frequencies in controls, 
only haplotypes with over 3% frequency in controls are listed.  The most common haplotype in 
cases and controls (GGACCC in controls and AGACCC in cases) differed by rs4804806 G/A 
only.  Most distortions in the haplotype distribution between cases and controls are caused by 
rs4804806 locus. 
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Figure 8: rs4804806 genotype frequencies in different populations from Hapmap 
(http://hapmap.ncbi.nlm.nih.gov/cgi-perl/snp_details_phase3?name=rs4804806&source 
=hapmap27_B36&tmpl=snp_details_phase3) 
 
2.7 Discussions 
In this study, we show that there are few genetic variants that cause amino acid changes 
in DC-SIGN.  This suggests that DC-SIGN is highly conservative through evolution, and this is 
consistent with other studies. (Barreiro, Patin et al. 2005)  We found fewer SNPs in the coding 
region of DC-SIGN compared to Barreiro’s group’s finding in 2005 in sub-Saharan African 
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samples from HapMap, and the LD pattern was also slightly different.  While this might be 
explained by different sample sizes, it also suggests that genetic characteristic of DC-SIGN in 
Tobago population may be different from that of the West African reference population.  This 
may reflect the genetic differentiation present in African populations or founder effects due to 
the restricted sample size of the original population.  Many SNPs are clustered in the 5’UTR of 
DC-SIGN and are in high linkage disequilibrium: this suggests that transcriptional modulation, 
rather than translational modulation may play an important role to alter DC-SIGN function. 
The association of DC-SIGN promoter haplotypes with PC suggests a role for the innate 
immune system in the etiology of this disease.  However, we don’t see any significant 
association of DC-SIGN haplotypes with HHV-8 infection.  It suggests that other pathogens may 
play a role in the elevated risk of PC in Tobago.  In 2006, Urisman et at. identified a novel 
gamma-retrovirus, xenotropic murine leukemia virus related virus (XMRV) in prostate tumors of 
patients homozygous for R462Q RNASEL variant.(Urisman, Molinaro et al. 2006)  This virus 
has been shown to be a PC risk factor and susceptibility mediated by the IFN antiviral pathway. 
(Dong, Kim et al. 2007)  DC-SIGN regulates several retroviral infections.  Therefore, the 
association we found between DC-SIGN promoter haplotypes and PC might be due to its 
regulatory role in determining susceptibility to XMRV infection in prostate tissues in the Tobago 
population.  Further, our results cannot rule out the role of HHV-8 infection on elevated PC risk 
in Tobago as suggested by epidemiological studies. (Hoffman, Bunker et al. 2004)   In 2008, 
Montgomery, Jenkins et al. reported that a SNP in the IL-6 gp130 signaling receptor is 
associated with increased PC risk among HHV-8 seropositive men in Tobago. (Montgomery 
2008)  This is suggests that HHV-8 may exploit genetic variations in genes other than DC-SIGN 
and contribute to PC risk in Tobago.   
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The DC-SIGN promoter SNP rs4804803 (-336 C/T) has been reported to be associated 
with viral infection. (Martin, Lederman et al. 2004; Despres, Sakuntabhai et al. 2005; 
Sakuntabhai, Turbpaiboon et al. 2005)  The C allele of this promoter SNP showed increased SP1 
binding activity in vitro and has been suggested to have a significant protective effect against 
severity of Dengue fever. (Sakuntabhai, Turbpaiboon et al. 2005)  On the other hand the C-336 
allele has been associated with elevated risk of parenteral acquisition of HIV-1 infection.  
(Martin, Lederman et al. 2004)  In our study, we did not see any statistically significant 
association with this SNP.  We only found marginal evidence for association at the C-336 and -
939C/T loci.  Although the functions of these two SNPs can be further analyzed by reporter gene 
assay, we find a much stronger association between haplotype distribution and PC risk, 
suggesting that the complex haplotype structure rather than any single SNP may be responsible 
for the elevated PC risk in the population of Tobago.  The observed association may also be 
caused by linkage disequilibrium with other variation found in this genomic region.   
The SNP rs4804806 (-4228) is the only locus which by itself showed significant 
association with PC risk in our study, and the A allele appears to be a risk allele for PC.  The A 
allele frequency is 40.1% in our Tobago controls, which is quite similar to that seen in the 
African YRI samples from Hapmap (Fig 8).  Hapmap data also showed that African populations 
have the highest frequencies for the A allele in all major populations, followed by Caucasians, 
then Asians. (Fig 8)  Interestingly, risk of PC follows the same order among these ethnic groups.  
We searched for consensus sequence transcription factor binding motifs near this locus using 
TRANSFAC (www.gene-regulation.com), and found that the A allele will actually add a 
putative transcription factor GR-beta binding site. Therefore the association we found at this 
locus might be explained by its regulation of DC-SIGN transcription.  However this needs to be 
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further explored since this locus is quite far away (over 4kb) from the gene, and there are several 
redundant putative GR-beta binding sites within the region 4kb upstream of DC-SIGN.  Thus it 
is also possible that this is not the causal locus, and the haplotype association observed at this 
locus could be due to its linkage disequilibrium with other causal variation.   
 
2.8 Conclusion 
To conclude, in this study we found significant association between promoter haplotypes 
in the DC-SIGN region and elevated risk of PC in Tobago population, while we did not see any 
association with serological evidence of HHV8 infection.  We also found significant association 
with PC for rs4804806 (G-4228A), although while its function still remains to be explored.  
Infectious agents other than HHV8, and other genes linked to DC-SIGN promoter haplotype, 
may be causal to elevated risk of PC in Tobago. 
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3.0  CHAPTER THREE: ASSOCIATION STUDY OF PSA RS266882 
POLYMORPHISM AND ANDROGEN RECEPTOR (CAG)n REPEAT 
LENGTH POLYMORPHISM WITH PC RISK AND PSA LEVEL IN 
TOBAGO POPULATION 
 
3.1 Background and Introduction 
3.1.1 Androgen and androgen receptor 
Androgens are essential for the growth and maintenance of both normal and malignant 
prostate cells. PC is believed to be androgen dependent, at least in early stages of the disease.  
Men who are castrated at an early age, or who have mutations that impair androgen production, 
do not develop prostate cancer. (1991; Wu and Gu 1991)  It has been reported that inhibition of 
androgen signaling in vitro results in apoptosis, and androgen ablation therapy results in 
temporary tumor regression in 70-80% of PC cases clinically.(Eder, Culig et al. 2000)  These 
studies suggest that the androgen and genes involved in androgen metabolism may play an 
important role in PC development.  
The androgen receptor (AR) is a nuclear hormone receptor, and is the central molecule of 
the androgen signaling pathway.  Ligand-dependent activation of AR by dihydrotestosterone and 
testosterone regulates a transcriptional cascade of many androgen dependent genes, including E-
cadherin, the prostate-specific antigen (PSA) gene, APS gene, etc.  The AR gene is located at 
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chromosome Xq11-12 and encodes a protein with two polymorphic regions in the transactivation 
domain of exon 1.  Polyglycine repeats (GGC)n  vary in length from 8 to 17, while polyglutamine 
repeats (CAG)n  are more variable, with repeat lengths from 9 to 29 in Caucasians.   The length 
of the CAG allele has been reported to be inversely related to transcriptional activity of AR, and 
several studies have suggested that short CAG alleles increase the relative risk of PC. 
(Giovannucci, Stampfer et al. 1997; Tut, Ghadessy et al. 1997; Xue, Irvine et al. 2000) 
 
3.1.2 Prostate-specific antigen (PSA) 
PSA is a serine protease produced by the secretory epithelial cells of the prostate gland. It 
can cleave insulin-like growth factor binding protein-3 and other proteins.  PSA has been widely 
used as a diagnostic marker of PC since the early 1990s.  Production of PSA is mediated by AR 
binding to the androgen response elements (ARE) in the promoter region of the PSA gene, 
located at chromosome 19q13.3-q13.4.  Its promoter region contains several AREs to which AR 
can bind.  A G/A polymorphism (rs266882) at -158bp, within ARE1 of PSA gene has been 
suggested to be associated with increased risk of PC and serum PSA level.  (Xue, Coetzee et al. 
2001; Cramer, Chang et al. 2003) Some studies further suggested that short CAG alleles of AR 
gene interact with the rs266882 G/G genotype, and such combination could significantly 
increase the relative risk of PC. (Xue, Irvine et al. 2000) 
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3.2 Specific Aims 
To test whether the rs266882 G/A polymorphism in the AREI of the PSA gene, or the 
(CAG)n repeat polymorphism in AR gene, is associated with risk of prostate cancer or serum 
PSA level in men from the Tobago population, and to determine any evidence of gene x gene 
interaction between these two polymorphisms. 
 
3.3 Experiment Design 
This specific aim was accomplished through the following steps: 
-Genotyping rs266882 G/A polymorphism in 167 cases and 320 controls drawn from the 
Tobago population, by TDI-FP. 
-Genotyping the AR (CAG)n repeat polymorphism in the same samples. 
-Calculating odds ratios (ORs) and confidence intervals (95% CI) to test if there is any 
association between PSA A/G genotype or AR (CAG)n repeat length and risk of PC, and to test 
whether there is any evidence of interaction between these two genes in determining the risk of 
PC in the Tobago population. 
-Using linear regression approach to test if genotypes at either of these loci are associated 
with serum PSA levels in controls and to test for interaction between these two genes in 
determining PSA levels.  
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3.4 Subjects and Methods 
3.4.1 Subjects 
Subjects were drawn from the Tobago Prostate Survey, an ongoing population based 
screening study of men 40-79 years old on the Caribbean Island of Tobago. (Bunker et al. 2002) 
as previously described.  Total of 167 PC cases and 320 age matched controls were used for this 
analysis. 
3.4.2 TDI-FP Genotyping on Rs266882 
PCR amplifications were carried out in a total reaction volume of 20 μl, containing 20ng 
of DNA, 4 pmoles of each primer, 4 nmoles of each dNTP, 2.0μl of 10xbuffer, 0.8μl of Mg2+ 
(Table 11) and 0.9U Taq DNA polymerase.  The amplification and amplicon check procedures 
were the same as described before.  Excess PCR primers and unincorporated dNTPs were 
degraded by the ExoSAP procedure (USB Corporation, Cleveland, Ohio, USA). 10μl PCR 
product was incubated with 10μl master mix of ExoSAP (1μl shrimp alkaline phosphatase, 0.1μl 
of exonuclease 23I, 1μl buffer and 8μl deionized water) at 37°C for 90 min., followed by 
denaturation at 95°C for 15 min. 
A template directed dye-terminator incorporation with fluorescence-polarization (TDI-FP) 
assay, as described in the previous chapter, was then performed using the described protocol.  
The FP primers and conditions are listed in Table 11.   
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Table 11: Amplification primer sequences and conditions and FP detection primer sequences for 
PSA AREI SNP rs266882 
SNPs ID 
(RS#) Primers 
Annealin
g Temp 
(°C) 
Mg2+ (mM) 
rs266882 
PCR-F TTGTATGAAGAATCGGGGATCGT 
60 2 
PCR-R TCCCCCAGGAGCCCTATAAAA 
FP-F ACTTGCTGTTCTGCAAT 
55  
FP-R CCTTCCCCTCCCTCTCGATC 
 
3.4.3 AR (CAG)n repeat Genotyping  
The AR (CAG)n was typed by polymerase chain reaction amplification from genomic 
DNA in the presence of a VIC-labeled forward primer, ARF:  5’-
TCCAGAATCTGTTCCAGAGCGTGC-3’.  Fragments were resolved on an ABI 3730 DNA 
analyzer (Applied Biosystems, Foster City, CA) and analyzed using GenMapper software 
version 3.7 (ABI).  Fragment sizes were assigned by comparison to a sequence verified fragment 
ladder generated by combining the PCR products of individuals of known (CAG)n length.  CAG 
repeat number ranged between 11 and 30 repeats in this sample (mean=19.7, SD=3.1), which is 
consistent with previously-reported CAG repeat lengths from populations of African ancestry. 
(Edwards, Hammond et al. 1992) The distribution in Tobago men was bimodal, with a nadir 
between 21 and 22 repeats.  They were grouped for analysis into short (21 repeats or fewer) and 
long (22 repeats or more) subgroups. 
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3.4.4 Measurement of PSA level 
Serum PSA levels were measured at the University of Pittsburgh Central Pathology 
Laboratory using the automated Microparticle Enzyme Immunoassay, Abbot AxSYM PSA assay 
(Abbott Laboratories, Abbott Park, IL).   
(www.abbottdiagnostics.com/Products/Instruments_by_Platform/default.cfm?system=AxSYM / 
AxSYM Plus&reg=us) 
 
3.5 Results 
3.5.1 Association analysis of PSA rs266882 genotype with PC 
Genotype information for rs266882 and its association with PC are summarized in Table 
12.  We did not see any evidence for association at this locus with PC risk. 
 
3.5.2 Association analysis of AR repeat length polymorphism with PC 
The CAG repeat length follows the binomial distribution pattern in our samples. The 
mean CAG repeat length was 19.7 ± 3.1 (mean ± SD) in cases and 20.6 ± 2.8 in controls.  Most 
studies used a cutoff of 22 repeats, to form two groups of repeat length, ≤ 22 (short) and > 22 
(long) repeats.  The (CAG)n length averaged 20.6 in our control samples, and the repeat length 
follows a binomial distribution in our samples (Fig 9), and 20 is the nadir as shown in Figure 9.  
We therefore also used a cutoff of 21 in our analysis to make sure different cutoffs won’t affect 
the results.  As shown in Table 13, repeat length was not associated with PC risk in our sample, 
at either cutoff standard.   
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Figure 9: Histogram of CAG repeat length distribution 
 
Table 12: ORs for PC associated with PSA rs266882 
Locus Genotype Cases N (%) Controls N (%) OR
a  (95% CI) 
PSA (rs266882, -
158bp) 
G/G 33 (19.8%) 72 (22.5%) 1.00  (Ref) 
G/A 79 (47.3%) 139 (43.4%) 0.81  (0.49-1.32) 
A/A 55 (32.9%) 109 (34.1%) 0.91  (0.53-1.53) 
ORa  adjusted for age 
 
3.5.3 Association analysis of interaction between PSA rs266882 GG and AR 
(CAG)n repeat length polymorphisms in determining risk of PC 
To test whether the GG genotype of PSA rs266882 interacts with short CAG repeat 
length and contributes to elevated PC risk together, as has been reported by some studies, we 
grouped our samples into two groups. One group was comprised of individuals with both the GG 
homozygote genotype and the short CAG allele, and the other group was comprised of all other 
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individuals.  Our result suggested that there was no association with PC at cutoffs of 21 or 22. 
(Table 14) 
 
Table 13: ORs for PC associated with AR CAG repeat length polymorphism 
Locus Genotype Cases N (%) Controls N (%) OR
a  (95% CI) 
AR (CAG)n (22 cut 
off) 
Short 128 (76.6%) 225 (70.3%) 1.00  (Ref) 
Long 39 (23.4%) 95 29.7%) 1.38  (0.90-2.13) 
AR (CAG)n (21 cut 
off) 
Short 101 (60.5%) 186 (58.1%) 1.00  (Ref) 
Long 66 (39.5%) 134 (41.9%) 1.10  (0.75-1.61) 
ORa  adjusted for age 
 
3.5.4 Regression analysis of PSA rs266882 genotype and AR CAG repeat length 
with serum PSA level 
To test whether PSA rs266882 genotype or AR (CAG)n polymorphism is associated with 
serum PSA level in controls, we carried out a regression analysis in the 320 controls using a 
regression module implemented in R. We also added the interaction term in the formula to see 
whether these genetic polymorphisms interact with each other.  Our results showed that neither 
PSA genotype nor AR (CAG)n repeat length is associated with serum PSA level in controls at 
the cut-off p-value of 0.05, and there is no interaction between these 2 loci.  (Table 15) 
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Table 14: ORs for PC associated with AR CAG repeat length polymorphism 
Locus Genotype Cases N (%) Controls N (%) OR
a  (95% CI) 
AR (CAG)n (22 cut 
off) 
GG+short 25 (15.0%) 53 (16.6%) 1.00  (Ref) 
Others 142 (85.0% 267 (83.4%) 0.89  (0.53-1.49) 
AR (CAG)n (21 cut 
off) 
GG+short 22 (13.2%) 47 (14.7%) 1.00  (Ref) 
Others 145 (86.8%) 273 (85.3%) 0.88  (0.51-1.52) 
 
Table 15: Regression analysis for PSA level with PSA and AR genotypes 
SL short=0, long=1, geno (aa=0, ag=1, gg=2) 
Coefficients Estimate Std. Error t value p-value (>|t|) 
pl$SL -0.2286 0.15463 -1.478 0.14 
pl$geno -0.10501 0.08473 -1.239 0.216 
pl$SL:p1$geno 0.12861 0.136 0.946 0.345 
  
3.6 Discussion 
Results from this study do not provide any evidence for an association with PC risk or 
PSA level for PSA -158 G/A genotypes or AR (CAG)n repeat length genotypes.   
Given the importance of PSA, regulation of its production is of biological and clinical 
importance.  Numerous studies have examined the function of rs26682 in PSA regulation, either 
alone or in combination with the AR gene.  Some studies reported that the GG genotype is 
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associated with risk of PC (Xue, Coetzee et al. 2001; Cicek, Liu et al. 2005; Severi, Hayes et al. 
2006), while some reported conversely that the A allele is associated (Gsur, Preyer et al. 2002; 
Medeiros, Morais et al. 2002; Lai, Kedda et al. 2007)  The same genotype groups were included 
our study, and we failed to find any evidence of association, in agreement with other studies. 
(Wang, Sato et al. 2003; Salinas, Austin et al. 2005)   
Although we did not find any association in this study, we cannot rule out the possible 
role of these phenotypes on PC risk in Tobago population.  First, it is possible that the risk 
estimates may accurately reflect the small magnitude of the relationship between the AR or PSA 
polymorphisms and PC risk, but our sample size it not large enough to achieve statistical 
significance.  Second, transactivation of genes by the AR is a complex process involving 
multiple other cofactors and other transcription factors, and influenced by the environment.  
Thus, there may be a true association, but only detectable in the presence of other gene-gene and 
gene-environment interactions. 
 
3.7 Conclusion 
No evidence was provided by our study that repeat length polymorphism in the AR gene or the 
rs266882 SNP in the PSA gene is associated with PC susceptibility or serum PSA level in the 
Tobago population. 
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4.0 CHAPTER FOUR: DISCUSSIONS 
 
4.1 Summary 
The two studies described here were designed to search for genetic variants that are 
associated with elevated risk of prostate cancer in the Tobago population. 
The first study explored the relationship between an immune related candidate gene, DC-
SIGN, and risk of prostate cancer.  We initially genotyped the entire DC-SIGN coding and non-
coding region in 41 controls and 39 cases from Tobago, and characterized the LD pattern of the 
DC-SIGN gene.  Our pilot screening found that most informative SNPs were clustered in the 
promoter region of DC-SIGN, and were in high LD with each other.  Therefore we further 
sequenced the 2kb promoter region of DC-SIGN in additional 153 cases and 172 controls from 
Tobago, and carried out association analysis for all the common SNPs we identified (MAF >10%) 
as well as determining their haplotype distribution.  Although we only found marginal 
association for two individual SNPs (rs4804803 and rs735240), we did find significant evidence 
of association for promoter haplotypes of DC-SIGN and risk of PC (p-value=0.03).  To test 
whether the haplotype association was due to LD with other nearby causal loci, two additional 
tag SNPs from HapMap were typed to extend the coverage into nearby chromosome regions.  
We found strong evidence of association for rs4804806 (-4228) itself (p-value < 0.01) as well as 
for promoter haplotype distributions with this locus. The A allele of this locus seems to be a 
dominant risk allele for elevated risk of PC, and the G allele seems to be protective against PC 
  50 
risk.  The function of rs4804806, and whether such association is due to linkage disequilibrium 
with other causal loci, remains to be explored. In the second study, we examined whether genetic 
variations of androgen receptor (AR) and PSA gene were associated with risk of prostate cancer 
or serum PSA level in the Tobago population.   It has been reported that the rs266882 G/A 
polymorphism in the AREI of PSA gene, and the (CAG)n repeat polymorphism in androgen 
receptor (AR) gene, are associated with risk of PC and serum PSA level in several studies, but 
the results we obtained were equivocal. 
In order to examine whether those two genetic variants affect PC risk or PSA level in the 
Tobago population, we genotyped rs266882 G/A, and CAG repeat length variants of AR, in 167 
cases and 320 controls.  Association analysis was conducted for each locus, and two genotypes 
were used to test for gene x gene interaction between these two loci.   Regression analysis was 
carried out for each locus and combined with serum PSA level in 320 controls.  Results from this 
study do not provide any evidence for association with PC risk or PSA level for PSA rs266882 
G/A genotypes or AR CAG repeat length genotypes. 
 
4.2 Future Directions 
         Our results suggested that the association for DC-SIGN promoter haplotype with PC 
cannot be explained by HHV infections.  It is important to test whether DC-SIGN contributes to 
PC risk by regulating other pathogens.  XMRV has been reported to be associated with PC risk.  
Assays to determine whether XMRV can use DC-SIGN as a receptor will be helpful.  
Alternatively, serological screening on other known DC-SIGN targeted infectious agents in our 
Tobago samples will also help to identify potential PC associated pathogens. 
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       Further function analysis on the rs4804806 A/G polymorphism is also necessary.  We 
propose reporter-gene assay in order to see if this SNP can alter promoter activity and regulate 
transcription.  This variant affects a putative GR-beta transcription binding site.  Therefore it is 
also helpful to test whether this variant has any effect on GB-beta binding in vitro. 
We also propose to do association studies in African Americans and African populations 
with high PC risk.  Such studies will provide us invaluable information on whether the DC-SIGN 
association we found in Tobago population is relevant in other African and African-decent 
populations.    
 
4.3 Public Health Significance 
Prostate Cancer is the most common cancer among men and the leading cause of cancer 
related deaths.  It remains a heavy public health burden.  We have shown a significant 
association of DC-SIGN promoter haplotypes with elevated risk of prostate cancer in the Tobago 
population.  Our data strongly supports the hypothesis that chronic inflammation and genes 
involved in immune response play an important role in PC.  The results from this dissertation 
lend support to exploring genetic causes and prevention of prostate cancer.  
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